How We Do It

Our certifications for NSF, ISO 9001, USDA Organic and Kosher, coupled with our “open book” transparency and rigorous self-regulation, ensures every client receives products that are safe and high-quality.

. .

Formulation & Finished Goods

Our team is committed to science-led innovation to create products that work for brands who care, delivering research-backed formulations in effective next-generation products across a wide variety of form factors.

Communication & Collaboration are Key

While most competitors provide straightforward formulations and standard forms, OBX works collaboratively with each of our clients, to develop sophisticated formulations in innovative form factors, and often leveraging new and cutting-edge technologies. The expertise of OBX’s in-house R&D team combined with its internal consumer insights and external efficacy studies, allows OBX to validate pre-commercial products, ensuring that every product is research-backed and effective for its desired purpose.

About the Team

Led by Andrea Baillo, PhD, and supported by a team of chemists and food scientists, the Formulation and Finished Goods R&D team is focused on the development and commercialization of research-backed finished products, combining effective formulations with new and existing product form factors to create next-generation cannabinoid products.

Ingredient production optimized for sophistication

With proven methods, a broadly experienced team, and a robust quality management system, our focus on sophistication has manifested itself as follows:

  • Broadest cannabinoid portfolio in the market
  • Pharma-grade purity specifications on cannabinoid isolates
  • Batch-to-batch consistency on custom specification distillates (eg 80% CBD, 10% CBG, 3% CBC)
  • In-house quality control lab
  • Robust quality management system to support NSF cGMP certification and ISO 9001 certification
  • Multiple market-leading technology partners such as Purissima and Nalu Biosciences

Method Development Capabilities

OBX’s method development capability enables the flexibility to adapt to potential regulatory conditions and implement cost-disruptive technologies for the production of cannabinoids, including:

  • Botanical hemp extraction, isolation, and purification
  • Botanical hemp derived starting materials plus conversion and purification
  • Biosynthetic starting materials downstream purification and scale up
  • Organic starting materials (such as terpenes) with synthetic pathways to produce cannabinoids
  • New Chemical Entity (NCE) development for the modification and purification of novel cannabinoids

About the Team

Led by David Temelkoff, a 14 year veteran of GSK, and supported by a team of both PhD and Masters scientists, the Ingredients R&D team is focused on the development and commercialization of novel cannabinoid ingredients and enhancement technologies

Method Development Capabilities

  • Botanical hemp extraction, isolation, and purification
  • Botanical hemp derived starting materials plus conversion and purification
  • Biosynthetic starting materials downstream purification and scale up
  • Organic starting materials (such as terpenes) with synthetic pathways to produce cannabinoids
  • New Chemical Entity (NCE) development for the modification and purification of novel cannabinoids

About the Team

Led by David Temelkoff, a 14 year veteran of GSK, and supported by a team of both PhD and Masters scientists, the Ingredients R&D team is focused on the development and commercialization of novel cannabinoid ingredients and enhancement technologies

Research & Innovation

Through our internal consumer insights, external university research, safety and toxicology studies, we allow science to lead the way, driving innovation and providing the broader industry with data-driven evidence to support category expansion.

Safety Comes First

OBX is one of the only companies in the industry investing in safety and efficacy research. Our research includes toxicology studies, university partnerships to support pre-clinical  studies for selected disease models, IHUT efficacy studies with Radicle Science, and internal consumer insights. These efforts position OBX to better understand the potential of cannabinoids and their ability to support better quality of life outcomes.

Development & Purification

OBX models its cannabinoid method development and purification approach after pharmaceutical discovery practices:

  • Initial method development to achieve target molecule specification
  • Process improvement to reduce purification steps and increase yield while still achieving target specification
  • Scale up modification, implementation, and optimization for commercialization

As Seen On

0
    0
    Your Cart
    Your cart is emptyReturn to Shop